뮤코다당증 치료 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global mucopolysaccharidosis treatment market size is expected to reach USD 13.72 Billion in 2034 from USD 5.33 Billion in 2025, growing at a CAGR of 11.07 during 2026-2034.This market is gaining momentum as awareness of rare genetic disorders increases and advancements in biotechnology enable more targeted treatment approaches. Mucopolysaccharidosis (MPS) refers to a group of inherited metabolic disorders caused by the deficiency of specific enzymes required to break down glycosaminoglycans. These conditions lead to progressive physical and neurological complications, requiring long-term and specialized medical care. Increasing focus on early diagnosis and intervention is significantly improving patient outcomes and driving demand for effective treatment options.

Growth is supported by advancements in enzyme replacement therapy (ERT), gene therapy research, and increased investment in orphan drug development. Pharmaceutical companies are actively developing therapies that address the underlying causes of MPS rather than just managing symptoms. Regulatory incentives, including fast-track approvals and funding for rare disease research, are encouraging innovation in this space. Additionally, improvements in diagnostic techniques, including genetic testing and newborn screening programs, are enabling earlier detection and treatment initiation. Patient advocacy groups and global awareness campaigns are also playing a crucial role in expanding access to treatment.

Future prospects indicate strong potential, with ongoing research focused on gene editing technologies and personalized medicine. The development of more effective and less invasive therapies will enhance patient compliance and quality of life. Emerging markets are expected to see gradual adoption as healthcare infrastructure improves and access to specialized treatments increases. As scientific understanding of rare diseases continues to evolve, the mucopolysaccharidosis treatment market is poised for sustained and transformative growth.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Treatment

• Enzyme Replacement Therapy (ERT)
• Others

By Disease Type

• Mucopolysaccharidosis Type I
• Mucopolysaccharidosis Type II
• Mucopolysaccharidosis Type IV A
• Mucopolysaccharidosis Type VI
• Others

By Route of Administration

• Intravenous
• Intracerebroventricular (ICV)

By End User

• Hospitals
• Specialty Clinics
• Others

COMPANIES PROFILED

• Shire (Takeda Pharmaceutical Company Limited), Denali Therapeutics, ArmaGen, REGENXBIO Inc., Sangamo Therapeutics, BioMarin, Lysogene, Abeona Therapeutics Inc., Ultragenyx Pharmaceutical, Genzyme Corporation

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL MUCOPOLYSACCHARIDOSIS TREATMENT MARKET: BY TREATMENT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Treatment
• 4.2. Enzyme Replacement Therapy (ERT) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL MUCOPOLYSACCHARIDOSIS TREATMENT MARKET: BY DISEASE TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Disease Type
• 5.2. Mucopolysaccharidosis Type I Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Mucopolysaccharidosis Type II Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Mucopolysaccharidosis Type IV A Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Mucopolysaccharidosis Type VI Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL MUCOPOLYSACCHARIDOSIS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Intravenous Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Intracerebroventricular (ICV) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL MUCOPOLYSACCHARIDOSIS TREATMENT MARKET: BY END USER 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End User
• 7.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL MUCOPOLYSACCHARIDOSIS TREATMENT MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Treatment
  • 8.2.2 By Disease Type
  • 8.2.3 By Route Of Administration
  • 8.2.4 By End User
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Treatment
  • 8.3.2 By Disease Type
  • 8.3.3 By Route Of Administration
  • 8.3.4 By End User
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Treatment
  • 8.4.2 By Disease Type
  • 8.4.3 By Route Of Administration
  • 8.4.4 By End User
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Treatment
  • 8.5.2 By Disease Type
  • 8.5.3 By Route Of Administration
  • 8.5.4 By End User
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Treatment
  • 8.6.2 By Disease Type
  • 8.6.3 By Route Of Administration
  • 8.6.4 By End User
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL MUCOPOLYSACCHARIDOSIS TREATMENT INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Denali Therapeutics
  • 10.2.2 ArmaGen
  • 10.2.3 REGENXBIO Inc
  • 10.2.4 Sangamo Therapeutics
  • 10.2.5 BioMarin
  • 10.2.6 Lysogene
  • 10.2.7 Abeona Therapeutics Inc
  • 10.2.8 Ultragenyx Pharmaceutical
  • 10.2.9 Genzyme Corporation